Skip to main content

AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

Active, not recruiting · Not applicable · NCT03732794

Conditions: Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation

At a glance

Research payments reported, 2025
$151,222
U.S. investigators named
14
Sites paid
15
Planned or actual enrollment
150

About the trial

Sponsor
AtriCure, Inc.
Tested
AtriCure CryoICE & AtriClip LAA Exclusion (device)
Dates
Started 2019-01-30; completion 2026-06
Results posted
Not yet

The primary objective of this study is to evaluate the safety and effectiveness of the AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with Left Atrial Appendage (LAA) exclusion using the AtriClip device.

From ClinicalTrials.gov, last updated 2024-10-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Atricure, Inc. reported $151,222 in research payments for this study in 2025 (130 payments).

Products named: Atricure Cryoice Cryosphere Cryoablation System

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.